Breaking News

Ajinomoto Bio-Pharma Services and Revance Therapeutics announced a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review. Aji Bio-Pharma will serve as a dual supply source and provide drug product manufacturing services for Revance at the company's aseptic manufacturing facility in San Diego, California.

Revance announced topline efficacy and safety results from its Phase 2 multicenter, open-label study of investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, which are comprised of glabellar lines, or GL, dynamic forehead lines, or FHL, and lateral canthal lines, or LCL, commonly known as crow's feet lines. In the Phase 2 study, 48 subjects were enrolled to receive a single treatment of DaxibotulinumtoxinA for Injection with a total study duration of 36 weeks. Subjects received 40, 32, and 48 units of DaxibotulinumtoxinA for Injection respectively in the glabellar complex, forehead and lateral canthal areas. The key endpoints for efficacy were the proportion of subjects achieving a score of none or mild wrinkle severity at maximum contraction at Week 4, as assessed on the Investigator Global Assessment Frown Wrinkle Severity, or IGA-FWS, Investigator Global Assessment Forehead Wrinkle Severity, or IGA-FHWS and Investigator Global Assessment Lateral Canthal Wrinkle Severity, or IGA-LCWS, respectively. The study measured duration of effect in responders.These duration measures were defined as the median time to return to baseline wrinkle severity or the time to loss of none or mild wrinkle severity, both based on investigator and subject assessments. DaxibotulinumtoxinA for Injection was generally safe and well tolerated when all three facial areas were injected simultaneously. There were no treatment-related serious adverse events, or SAEs. The most common adverse events, or AEs, were injection site erythema, facial discomfort and headache. No eyelid or brow ptosis was reported. Participants used a 7-point Subject Global Satisfaction with Treatment Questionnaire to rate their satisfaction with treatment of DaxibotulinumtoxinA for Injection. At Week 4, 100% of participants reported being at least "Somewhat Satisfied" with the treatment in all three areas, and 83%, 78.7%, and 80.9% reported being "Very Satisfied" with the treatment of their glabellar lines, forehead lines, and crow's feet, respectively.

Tennessee Gov. Bill Lee, Department of Economic and Community Development Commissioner Bob Rolfe and Revance Therapeutics officials announced that the company will relocate its headquarters from Silicon Valley's Newark, California, to Nashville, Tennessee.